statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

As per the latest Enforcement Report by the US Food and Drug Administration (USFDA), Lupin is recalling 26,352 bottles of Rifampin Capsules (300 mg), an antibiotic medication in the US market.

Lupin, Glenmark recall drugs in US market: USFDA

The US Food and Drug Administration (USFDA) had issued eight observations under Form 483 after inspecting the company's Kothur-based formulation facility.

Natco Pharma gets warning letter from USFDA for Telangana plant

Lupin recalled 26,352 bottles of Rifampin capsules, used in the treatment of tuberculosis

Lupin, Glenmark, Natco recall products from US markets

While most of the corporates have shown double digit value growth, unit growth remains a challenge for the Indian pharma market, according to analysts

Indian pharmaceutical market registers 9.5% growth in March

Geojit Financial Services recommended accumulate rating on NATCO Pharma with a target price of Rs 1116 in its research report dated March 27, 2024.

Accumulate NATCO Pharma; target of Rs 1116: Geojit Financial Services

SBI Life Insurance Company ended at new closing high and formed strong bullish candlestick pattern with healthy volumes on the daily timeframe, after a decisive breakout of horizontal resistance trendline.

Trade Spotlight | Your strategy to deal in Mahindra &amp; Mahindra, SBI Life, Natco Pharma today

Around 70% of stocks in Nifty MidCap 100 and Nifty SmallCap 100 indices witnessed a rise in mutual fund stakes in December 2023 quarter, according to Ace Equities data.

MFs raise stakes in 70% Nifty smallcap, midcap stocks in Q3, despite caution

Experts feel 21,000 is expected to be key to watch in the current week, which is full of events including interim budget, and FOMC meet outcome, while on the higher side, 21,500 is likely to be key hurdle, followed by the resistance of 21,700 levels.

As D-St goes volatile, experts line up 10 stocks to bet on in Feb

NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. It operates through the following segments: Domestic Formulations, International Formulations, and Active Pharmaceutical Ingredients. The Domestic Formulations segment operates in the divisions of oncology, pharma specialties and CnD. The International Formulations segment exports its FDF products from India to several international geographies either through its local partners or directly through its subsidiaries such as in Canada and Brazil. The Active Pharmaceutical Ingredients segment is strategically important as it develops APIs for the captive consumption of many of NATCO's critical FDF products in addition to supplying to direct customers. The company was founded by Venkaiah Chowdary Nannapaneni in 1981 and is headquartered in Hyderabad, India.

Watchers	244
52-Wk Low	609.15
52-Wk High	1,108.35

Volume	8,089.00
52-Wk High	1,108.35
52-Wk Low	609.15

Current Price	1,004.90
Prev Close	993.95
Open	998.00
Dividend Yield	0.98%
50-Day Moving Average	987.58
Beta	0.00
Avg. Volume	657,412.60
PE Ratio	14.04

52-Week High	1,108.35
52-Week Low	609.15
Market Capitalization	178.23B
EPS	70.86
Price to Book	3.36
Revenue Per Employee	8.52M
Enterprise Value/EBITDA	9.04

NATCOPHARM.NSE NATCO Pharma Ltd.

About

Feed

News

Sentiment

Fundamentals